What's new? Log in Free sign up

Home
Sectors & IndustriesSectors
Earnings
IPOs
Transcripts
Insider
Institutional
Splits

BNTX Dashboard
Financials
Filings
Holdings
Transcripts
ETFs
Insider
Institutional
Shorts
6-K Filing

BioNTech SE (BNTX) 6-KPfizer and BioNTech Announce Positive Topline Data for Influenza and COVID-19

Filed: 26 Oct 23, 4:08pm

Free signup for more

Track your favorite companies
Receive email alerts for new filings
Personalized dashboard of news and more
Access all data and search results

Search this filing

All

Tables only

Footnotes only

Pre-defined:

Table of contents

Filing tables

Export all tables to Excel

Filing exhibits

6-K Current report (foreign)
99.1 Pfizer and BioNTech Announce Positive Topline Data for Influenza and COVID-19

BNTX similar filings

7 Nov 23 1 Welcome & Introductory Remarks Ryan Richardson Chief Strategy Officer
6 Nov 23 Current report (foreign)
6 Nov 23 BioNTech Announces Third Quarter 2023 Financial Results
26 Oct 23 Pfizer and BioNTech Announce Positive Topline Data for Influenza and COVID-19
23 Oct 23 BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
16 Oct 23 BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023
16 Oct 23 Update Regarding Pfizer’s Statement on COMIRNATY-Related Write-Offs

Filing view

Default size S M L
Default font Times Arial

External links

View on EDGAR (sec.gov)

Share this filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF OCTOBER 2023

COMMISSION FILE NUMBER 001-39081

BioNTech SE
(Translation of registrant’s name into English)

An der Goldgrube 12

D-55131 Mainz

Germany

+49 6131-9084-0
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

On October 26, 2023, BioNTech SE and Pfizer Inc. announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age. The press release is attached hereto as Exhibit 99.1.

SIGNATURE

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


			BioNTech SE


			By:			/s/ Dr. Sierk Poetting
						Name: Dr. Sierk Poetting
						Title: Chief Operating Officer

Date: October 26, 2023

EXHIBIT INDEX



Exhibit			Description of Exhibit

99.1			Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

Resources

Knowledgebase
Log In
Register

Company

About
Contact
Solutions

Products

Deal Roadshow
DealVDR
Evercall
Finsight.com

CapEdge

Earnings Calendar
Earnings Transcripts
EDGAR Filing Screener
IPO Calendar

Compliance
Privacy
Security
Terms

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.